Mucoadhesive nanoliposomal formulation for vaginal delivery of an antifungal

Drug Development and Industrial Pharmacy

Volumn 39, Issue 9, 2013, Pages 1328-1337

  Karimunnisa, Shaikh ^a   Atmaram, Pawar ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

Author keywords

Ciclopirox olamine; Elastic; Liposome; Mucoadhesion; Rheology; Vulvovaginal candidiasis

Indexed keywords

CARBOMER; CICLOPIROXOLAMINE; LIPOSOME; NANOMATERIAL;

ANIMAL EXPERIMENT; ANTIFUNGAL ACTIVITY; ARTICLE; DILUTION; DRUG RELEASE; DRUG STABILITY; FEMALE; FLOW KINETICS; GEL; IN VITRO STUDY; LIPOSOMAL DELIVERY; MUCOADHESION; NONHUMAN; OSCILLATION; PH; SHEEP; SPECTROFLUOROMETRY; STRESS; SUSTAINED DRUG RELEASE; TEMPERATURE DEPENDENCE; VAGINA DISCHARGE; VISCOMETRY; ZETA POTENTIAL;

ADHESIVENESS; ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG STABILITY; ELASTICITY; FEMALE; GELS; LIPOSOMES; MUCOUS MEMBRANE; NANOSTRUCTURES; PHYSICOCHEMICAL PHENOMENA; PYRIDONES; SHEEP, DOMESTIC; SOLUBILITY; VAGINA; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 84881185744     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.707204     Document Type: Article

References (44)

1. Wassen L, Jertborn M. (2005). Kinetics of local and systemic immune responses after vaginal immunization with recombinant cholera toxin B subunit in humans. Clin Diagn Lab Immunol, 12:447-452. (Pubitemid 41175340)
2. Fraillery D, Zosso N, Nardelli-Haefliger D. (2009). Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like particles. Vaccine, 27:2326-2334.
3. Zetola NM, Pilcher CD. (2007). Diagnosis and management of acute HIV infection. Infect Dis Clin North Am, 21:19-48, vii. (Pubitemid 46729635)
4. Weber J, Desai K, Darbyshire J; Microbicides Development Programme. (2005). The development of vaginal microbicides for the prevention of HIV transmission. PLoS Med, 2:e142.
5. Veazey RS, Klasse PJ, Ketas TJ, Reeves JD, Piatak M Jr, Kunstman K et al. (2003). Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J Exp Med, 198:1551-1562. (Pubitemid 37467169)
6. Perioli L, Ambrogi V, Venezia L, Giovagnoli S, Pagano C, Rossi C. (2009). Formulation studies of benzydamine mucoadhesive formulations for vaginal administration. Drug Dev Ind Pharm, 35:769-779.
7. D'Cruz OJ, Erbeck D, Uckun FM. (2005). A study of the potential of the pig as a model for the vaginal irritancy of benzalkonium chloride in comparison to the nonirritant microbicide PHI-443 and the spermicide vanadocene dithiocarbamate. Toxicol Pathol, 33:465-476. (Pubitemid 40995486)
8. Garg S, Anderson RA, Chany CJ 2nd, Waller DP, Diao XH, Vermani K et al. (2001). Properties of a new acid-buffering bioadhesive vaginal formulation (ACIDFORM). Contraception, 64:67-75. (Pubitemid 32787100)
9. Haineault C, Gourde P, Perron S, Désormeaux A, Piret J, Omar RF et al. (2003). Thermoreversible gel formulation containing sodium lauryl sulfate as a potential contraceptive device. Biol Reprod, 69:687-694. (Pubitemid 36885976)
10. Mahaguna V, McDermott JM, Zhang F, Ochoa F. (2004). Investigation of product quality between extemporaneously compounded progesterone vaginal suppositories and an approved progesterone vaginal gel. Drug Dev Ind Pharm, 30:1069-1078. (Pubitemid 39577999)
11. Taylor SJ, Peat JK, Armour CL. (1999). An evaluation of prostaglandin E2 vaginal gel use in practice. J Clin Pharm Ther, 24:303-310. (Pubitemid 29403324)
12. Garg S, Jambu L, Vermani K. (2007). Development of novel sustained release bioadhesive vaginal tablets of povidone iodine. Drug Dev Ind Pharm, 33:1340-1349.
13. Milani M, Molteni B, Silvani I. (2000). Effect on vaginal pH of a polycarbophil vaginal gel compared with an acidic douche in women with suspected bacterial vaginosis: a randomised, controlled study. Curr Therap Res, 61:781-788.
14. das Neves J, Bahia MF. (2006). Gels as vaginal drug delivery systems. Int J Pharm, 318:1-14. (Pubitemid 43963297)
15. Pavelic Z, Skalko-Basnet N, Jalsenjak I. (1999). Liposomes containing drugs for treatment of vaginal infections. Eur J Pharm Sci, 8:345-351. (Pubitemid 29325027)
16. Pavelic Z, Skalko-Basnet N, Schubert R. (2001). Liposomal gels for vaginal drug delivery. Int J Pharm, 219:139-149. (Pubitemid 32391373)
17. Pavelic Z, Skalko-Basnet N, Jalsenjak I. (2004). Liposomal gel with chloramphenicol: characterisation and in vitro release. Acta Pharm, 54:319-330. (Pubitemid 40143817)
18. Pavelic Z, Skalko-Basnet N, Filipovic-Grcic J, Martinac A, Jalsenjak I. (2005). Development and in vitro evaluation of a liposomal vaginal delivery system for acyclovir. J Control Release, 106:34-43. (Pubitemid 41140079)
19. Mashburn J. (2006). Etiology, diagnosis, and management of vaginitis. J Midwifery Womens Health, 51:423-430. (Pubitemid 44615970)
20. Denning DW, Hope WW. (2010). Therapy for fungal diseases: opportunities and priorities. Trends Microbiol, 18:195-204.
21. Albertinia B, Passerinia N, Sabatinoa M, Vitali B, Brigidi P, Rodrigueza L. (2009). Polymer-lipid based mucoadhesive microspheres prepared by spray-congealing for the vaginal delivery of econazole nitrate. Eur J Pharm Sci, 6:591-601.
22. Carrillo-Muñoz AJ, Brió S, Alonso R, del Valle O, Santos P, Quindós G. (2002). Ciclopiroxolamine: in vitro antifungal activity against clinical yeast isolates. Int J Antimicrob Agents, 20:375-379.
23. Available at: www.profarma.az/en/preparat/5.html
24. Available at: www.cipladoc.com/therapeutic/admin.php?mode= prod&action=disp&id=635
25. Shaikh KS, Pawar AP. (2010). Liposomal delivery enhances cutaneous availability of ciclopirox olamine. Lat Am J Pharm, 29:763-770.
26. Walash MI, Rizk MS, Eid MI, Fathy Mel S. (2006). Spectrofluorimetric determination of ciclopirox olamine via ternary complex with Tb(III) and EDTA. Acta Pharm, 56:431-440. (Pubitemid 44863010)
27. Shaikh KS, Chellampillai B, Pawar AP. (2010). Studies on nonionic surfactant bilayer vesicles of ciclopirox olamine. Drug Dev Ind Pharm, 36:946-953.
28. Skalko N, Ajkovac M, Jalšenjak I. (1998). Liposomes with metronidazole for topical use: the choice of preparation method and vehicle. J Liposome Res, 8:283-293. (Pubitemid 28268268)
29. Valenta C. (2005). The use of mucoadhesive polymers in vaginal delivery. Adv Drug Deliv Rev, 57:1692-1712. (Pubitemid 41444256)
30. Owen DH, Katz DF. (1999). A vaginal fluid simulant. Contraception, 59:91-95. (Pubitemid 29244754)
31. Costa P, Sousa Lobo JM. (2001). Modeling and comparison of dissolution profiles. Eur J Pharm Sci, 13:123-133. (Pubitemid 32288781)
32. Neves J, Silva MV, Gonçalves MP, Amaral MH, Bahia MF. (2009). Rheological properties of vaginal hydrophilic polymer gels. Curr Drug Delivery, 6:83-92.
33. Tavares GM, Galdorfini CB, Ribeiro HM, Lucia IV. (2010). Rheological characterization of hydrophilic gels. J Disper Sci Technol, 31:820-825.
34. Chang JY, Oh YK, Choi HG, Kim YB, Kim CK. (2002). Rheological evaluation of thermosensitive and mucoadhesive vaginal gels in physiological conditions. Int J Pharm, 241:155-163. (Pubitemid 34667075)
35. Rudraraju VS, Wyandt CM. (2005). Rheology of Microcrystalline Cellulose and Sodiumcarboxymethyl Cellulose hydrogels using a controlled stress rheometer: part II. Int J Pharm, 292: 63-73. (Pubitemid 40255789)
36. Owen DH, Peters JJ, Lavine ML, Katz DF. (2003). Effect of temperature and pH on contraceptive gel viscosity. Contraception, 67:57-64. (Pubitemid 36084290)
37. Owen DH, Peters JJ, Katz DF. (2000). Rheological properties of contraceptive gels. Contraception, 62:321-326. (Pubitemid 32182420)
38. Lai BE, Xie YQ, Lavine ML, Szeri AJ, Owen DH, Katz DF. (2008). Dilution of microbicide gels with vaginal fluid and semen simulants: effect on rheological properties and coating flow. J Pharm Sci, 97:1030-1038. (Pubitemid 351293901)
39. Sassi AB, McCullough KD, Cost MR, Hillier SL, Rohan LC. (2004). Permeability of tritiated water through human cervical and vaginal tissue. J Pharm Sci, 93:2009-2016. (Pubitemid 39045482)
40. Dittgen M, Durrani M, Lehman K. (1997). Acrylic polymers: a review of pharmaceutical applications. S T P Pharm Sci, 7:403-437.
41. Boulmedarat L, Grossiord JL, Fattal E, Bochot A. (2003). Influence of methyl-β-cyclodextrin and liposomes on rheological properties of Carbopol 974P NF gels. Int J Pharm, 254:59-64. (Pubitemid 36259811)
42. Owen DH, Peters JJ, Katz DF. (2001). Comparison of the rheological properties of Advantage-S and Replens. Contraception, 64:393-396. (Pubitemid 34143210)
43. Chopra S, Motwani SK, Iqbal Z, Talegaonkar S, Ahmad FJ, Khar RK. (2007). Optimisation of polyherbal gels for vaginal drug delivery by Box-Behnken statistical design. Eur J Pharm Biopharm, 67:120-131. (Pubitemid 46991318)
44. das Neves J, Amaral MH, Bahia MF. (2008). Performance of an in vitro mucoadhesion testing method for vaginal semisolids: influence of different testing conditions and instrumental parameters. Eur J Pharm Biopharm, 69:622-632.